New Agents Committee

The New Agents Committee (NAC) selects new anti-cancer treatments for early clinical trials.

NAC members are expert in early clinical trials of novel agents and other aspects of drug development. Proposals and meetings are confidential. NAC-approved novel agents in development include: molecularly targeted small molecules, cytotoxic agents, antibodies, vaccines, viral gene therapy, immunotherapy, cell therapy, radioimmunotherapy, diagnostics and imaging agents.

Research areas

The NAC is interested in proposals for scientifically-driven trials of novel unregistered anti-cancer agents. NAC reviews:

  • Exploratory/preclinical development prior to a clinical trial
  • Phase 1 trials, including first-in-human and first-in-class
  • Combinations trials of unregistered and registered agents
  • Early phase 2 hypothesis-testing trials

How proposals are judged

Proposals are subject to external, international peer review and are judged on the basis of:

  • Scientific rationale and importance
  • Uniqueness/novelty of the target or agent
  • Significance of the proposed trial and its endpoints
  • Clinical need
  • Quality of data in relevant models
 

Committee chairs and members

Chair of the New Agents Committee

Professor Pat LoRusso – Yale Cancer Center

Exploratory Chair of the New Agents Committee

Professor Neil Carragher – University of Edinburgh

NAC members

Professor Udai Banerji – Institute of Cancer Research

Professor Sarah Blagden – University of Oxford

Professor John Chester – Alder Hey Children's Hospital, Liverpool

Dr Andrew Davies – School of Medicine, University of Southampton

Professor Gail Eckhardt – University of Texas Austin

Professor Linda Hakes – Independent, Germany

Professor Margaret Harnett – University of Glasgow

Professor Andrew Hughes – University of Manchester

Mr Bo Kara – Evox Therapeutics

Professor Richard Kennedy – Queen’s University Belfast

Professor Stefan Pfister – DFKZ Heidelberg

Dr Greg Reyes – Independent, San Diego

Dr Olivia Rossanese – Institute of Cancer Research

Professor Manuel Salto-Tellez – Queen’s University Belfast

Professor Kjetil Tasken – University of Oslo

Professor Anne Thomas – University of Leicester

Professor Dr Jaap Verweij – Erasmus University Rotterdam

Professor Steve Wedge – University of Newcastle

Dr Tim Yap –  M D Anderson, University of Texas

Contact for this committee

Kate Searle

Kate Searle

Research Funding Manager

Kate.Searle@cancer.org.uk

Tel: +44 (0) 20 3469 6929

Schemes reviewed by this committee

Discover more like this

Drug Discovery Committee

Funds biotherapeutic and small molecule drug discovery.

Clinical Research Committee

Oversees funding and endorsement of investigator-led clinical trials